ESMO 2020: Overall Survival With Weekly Dose-Dense Chemotherapy for Ovarian Cancer
Posted: Friday, October 9, 2020
Although a previous study, JGOG3016, found improved survival among Japanese women with ovarian cancer who received weekly dose-dense chemotherapy compared with women who received standard chemotherapy, findings from the phase III ICON8 trial suggested otherwise. Andrew R. Clamp, MRCP, PhD, of the Christie NHS Foundation Trust, Manchester, United Kingdom, and colleagues found that weekly dose-dense chemotherapy may be a safe alternative to standard chemotherapy among women with epithelial ovarian cancer; however, it does not appear to improve overall survival. The findings were presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 (Abstract 805O).
The research team assigned 1,566 women with epithelial ovarian cancer to three different treatment arms: arm 1 received standard chemotherapy (n = 522), arm 2 received weekly paclitaxel (n = 523), and arm 3 received weekly carboplatin and paclitaxel (n = 521). Survival results compared arm 2 versus arm 1 and arm 3 versus arm 1. The patient pool was primarily European.
There were no significant differences in overall or progression-free survival results between arms 2 and 1 (P > .05) or arms 3 and 1 (P > .05). The median overall survival was 47.4 months, 54.1 months, and 53.4 months in arms 1, 2, and 3, respectively. The progression-free survival results among the three treatment groups were also comparable. The mean progression-free survival was 25 months, 25.5 months, and 25.9 months, for arms 1, 2, and 3, respectively. Overall, 923 patients died (arm 1: n = 319; arm 2: n = 300; arm 3: n = 304).
“It is possible that ethnic pharmacogenomic differences underlie the discordant outcomes between ICON8 and JGOG3016, and that weekly dose-dense paclitaxel treatment could still be considered as a first-line treatment option for Japanese women with epithelial ovarian cancer,” the researchers concluded.
Disclosure: For full disclosures of the study authors, visit oncologypro.esmo.org.
